Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery

Scott D. Berkowitz, MD, Keith A A Fox, MBBS, Stephan Schmidt, Jeffrey I Weitz, MD FRCPC, FACP, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann

Blood (2017) 130 (Supplement 1): 3718.

https://doi.org/10.1182/blood.V130.Suppl_1.3718.3718

Published: 2017

Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

Scott D. Berkowitz, MD, Jeffrey I Weitz, MD FRCPC, FACP, Stephan Schmidt, Keith A A Fox, MBBS, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann

Blood (2017) 130 (Supplement 1): 1104.

https://doi.org/10.1182/blood.V130.Suppl_1.1104.1104

Published: 2017

Journal Articles

The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation

Xiaoyu Yan, PhD MSc, Gary Peters, MD, Amarnath Sharma, Partha Nandy, Christopher Nessel, MD, Dirk Garmann, Stefan Willmann, Anne Hermanowski-Vosatka, Alexander Solms, Scott D. Berkowitz, MD, Theodore E Spiro, MD, Keith A A Fox, MBBS, Jeffrey I Weitz, MD FRCPC, FACP, Stephan Schmidt, Jonathan P Piccini, Manesh Patel, Richard C Becker, Liping Zhang

Blood (2017) 130 (Supplement 1): 1107.

https://doi.org/10.1182/blood.V130.Suppl_1.1107.1107

Published: 2017

Journal Articles

Quantitative Benefit–Risk Assessment of Rivaroxaban for the Prevention of Venous Thromboembolism.

Bennett Levitan, MD, PhD, Zhong Yuan, MD, PhD, Alexander GG Turpie, MD, Richard J Friedman, MD, Martin Homering, MSPH, Jesse A Berlin, ScD, Scott D Berkowitz, MD, FACP, Peter M DiBattiste, MD, FACC

Blood (2009) 114 (22): 169.

https://doi.org/10.1182/blood.V114.22.169.169

Published: 2009

Journal Articles

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Sylvia Haas, MD, Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, MD, PhD, Bengt Eriksson, MD, PhD, Kai Vogtlaender, Dagmar Kubitza, MD, Wolfgang Mueck, PhD, Michael Gent, DSc, Frank Misselwitz, MD, Scott D Berkowitz, MD, FACP

Blood (2009) 114 (22): 2099.

https://doi.org/10.1182/blood.V114.22.2099.2099

Published: 2009

Journal Articles

Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4

Alexander GG Turpie, MD, Kenneth A. Bauer, MD, Bruce Davidson, MD, Michael Gent, MD, Louis Kwong, MD, Michael Rud Lassen, MD, Fred Cushner, MD, Paul Lotke, MD, Scott D. Berkowitz, MD, FACP, Tiemo Joerg Bandel, Frank Misselwitz, MD, William Fisher, MD

Blood (2008) 112 (11): 35.

https://doi.org/10.1182/blood.V112.11.35.35

Published: 2008

Journal Articles

Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery

Kenneth A. Bauer, MD, Martin Homering, Scott D. Berkowitz, MD, FACP

Blood (2008) 112 (11): 436.

https://doi.org/10.1182/blood.V112.11.436.436

Published: 2008

Journal Articles

Bleeding Indicators and Wound Complications with Ximelagatran and Warfarin after TKR: Findings from 3 Clinical Trials.

Scott D. Berkowitz, MD, Charles W. Francis, MD, Jennifer McElhattan, MS, Clifford W. Colwell, Jr., MD

Blood (2004) 104 (11): 1771.

https://doi.org/10.1182/blood.V104.11.1771.1771

Published: 2004

Journal Articles

Efficacy wnd Bleeding with Ximelagatran and Warfarin after TKR: Pooled Subgroup Analysis of 3 Phase III Trials.

Scott D. Berkowitz, MD, Jennifer McElhattan, MS, Charles W. Francis, MD, Clifford W. Colwell, Jr., MD

Blood (2004) 104 (11): 1777.

https://doi.org/10.1182/blood.V104.11.1777.1777

Published: 2004

NARROW

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation

Quantitative Benefit–Risk Assessment of Rivaroxaban for the Prevention of Venous Thromboembolism.

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4

Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery

Bleeding Indicators and Wound Complications with Ximelagatran and Warfarin after TKR: Findings from 3 Clinical Trials.

Efficacy wnd Bleeding with Ximelagatran and Warfarin after TKR: Pooled Subgroup Analysis of 3 Phase III Trials.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only